



For immediate release

7 February 2006

ANGEL BIOTECHNOLOGY HOLDINGS PLC
(“Angel” or “the Company”)

Angel and ReNeuron announce GMP Stem cell contract

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, that was recently admitted on AIM, and ReNeuron Group plc, a leading player in the field of stem cell therapeutics, are pleased to announce details of a Good Manufacturing Practice (GMP) manufacturing contract. Terms of the contract have not been disclosed.

Under the contract Angel will manufacture a GMP cell bank for ReNeuron’s ReN005 adult stem cell line for Huntington’s disease.

This contract strengthens the relationship with ReNeuron which was founded when the companies joined forces in a consortium that was awarded a £2.2m, 3-year, grant by the UK Department of Trade and Industry (DTI) in January 2005. The consortium, led by ReNeuron, is undertaking a bioprocessing project entitled ‘Therapeutic Products from Human Stem Cells’ in which Angel is the manufacturing partner. Angel’s key role is to establish the capability to manufacture and scale-up stem cell technologies to GMP standards for clinical trials and for their application as therapeutic products.

Angel’s licenced facility in Edinburgh, specialising in the manufacture of cell based therapies, will be utilised for the contracted GMP manufacturing work. This facility, rapidly becoming a centre of excellence for stem cell manufacturing, is located at Pentlands Science Park, Edinburgh and was licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) in July under the European Clinical Trials Directive (2001/20/EU). All clinical trials within Europe are subject to the requirements of this directive and Angel’s Manufacturing Licence for Investigational Medicinal Products (IMPs) authorises Angel to manufacture biopharmaceuticals to be used in clinical trials.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: “Angel is delighted to have contracted with ReNeuron to provide them with cells manufactured to GMP for use in subsequent clinical trials. The technical transfer to Angel of their technology has gone extremely well and we look forward to further collaborations in the future. This contract moves Angel to the forefront of stem cell manufacturing and is an endorsement of our MHRA licensed GMP facilities in Edinburgh and the skill of the Angel team. We also look forward to continuing to work with ReNeuron in other directions as part of the Stem Cell Consortium.”

Michael Hunt, Chief Executive Officer of ReNeuron, said: “We are delighted to be working with Angel as our manufacturing partner on the ReN005 Huntington’s programme. Angel is an emerging leader in the out-sourced GMP manufacture of cell-based therapies. Their capabilities play well to one of ReNeuron’s key competitive

strengths: the ability to generate stable and efficacious stem cell lines which are capable of rapid and early scale-up for the clinic and beyond. We look forward to a continuing partnership with Angel both on this contract and with the stem cell bioprocessing consortium.”

For further information, please call:

Angel Biotechnology Holdings plc
Gordon Sherriff – COO

Tel 01670 591920
Tel 07951 057016

Buchanan Communications
Lisa Baderoon/Mary-Jane Johnson

Tel 020 7466 5000

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.

About ReNeuron Plc

ReNeuron is a leading, UK-based adult stem cell therapy business. The Company is applying its novel c-mycER^{TAM} stem cell platform technology in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.

The Company's lead stem cell therapy, ReN001 for chronic stroke disability, is in late pre-clinical development. The Company plans to file for approval to commence initial clinical trials in stroke later this year, with trials commencing as soon as possible thereafter. The Company has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington's disease, a rare, genetic and fatal neurodegenerative disorder which affects around 1 in 100,000 people. This programme is in pre-clinical development. In addition to these programmes, ReNeuron is developing stem cell therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.

The Company successfully completed its flotation on the London AIM market in August 2005. ReNeuron's shares are traded under the symbol RENE.L.

Further information on ReNeuron and its products can be found at www.reneuron.com.